Constellation Pharmaceuticals, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jigar Raythatha
- Full Time Employees
- 154
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 215 1st St Ste 200 Cambridge MA United States of America 02142
- IPO Date
- Jul 19, 2018
- CIK
- 0001434418
- Website
- constellationpharma.com
- Similar Companies
- Business
- Constellation Pharmaceuticals, Inc. (CNST) develops small-molecule drugs targeting cancer epigenetics and other diseases through precision modulation of gene expression. The company offers a pipeline of investigational therapies including pelabresib (CPI-0610), a BET inhibitor for myelofibrosis in combination with ruxolitinib; zanzalintinib (XP-5000), a next-generation TKI for renal cell carcinoma and other solid tumors; and additional preclinical and clinical candidates focused on EZH2, HDAC, and other epigenetic targets. It provides research services and collaborates with partners on co-development of oncology drugs; founded in 2007 and headquartered in Boston, Massachusetts, Constellation operates primarily in the United States with global clinical trial presence in North America, Europe, and Asia-Pacific targeting pharmaceutical companies, academic institutions, and patients with hematologic malignancies and solid tumors. In recent developments, the company was acquired by Genentech, a member of the Roche Group, in 2022 for approximately $1.3 billion, integrating its epigenetic programs into Roche's oncology portfolio; this followed positive phase 2 data for pelabresib in 2021 and ongoing advancements in its pipeline without subsequent name changes or major reorganizations as of late 2025.
MorphoSys to Complete Transformational Acquisition of Constellation Pharmaceuticals, Bolstering Its Position in Hematology-Oncology
Constellation Pharmaceuticals Provides an Update from the Ongoing MANIFEST Study of Pelabresib
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Constellation Pharmaceuticals, Inc. - CNST
Why Constellation Pharmaceuticals Stock Was Crushing It This Week
SHAREHOLDER ALERT: WeissLaw LLP Investigates Constellation Pharmaceuticals, Inc.
Why Constellation Pharmaceuticals Stock Is Skyrocketing Today
Shareholder Alert: Ademi LLP investigates whether Constellation Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with MorphoSys
Constellation Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Constellation Pharmaceuticals, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – CNST
Constellation Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Constellation Pharmaceuticals, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – CNST
Why Constellation Pharmaceuticals Is Soaring Today
CNST Stock Price: Over 60% Increase Pre-Market Explanation
MorphoSys to Acquire Constellation Pharmaceuticals
Constellation Pharmaceuticals to Participate in Jefferies Virtual Healthcare Conference
Constellation Pharmaceuticals, Inc. (CNST) CEO Jigar Raythatha on Q1 2021 Results - Earnings Call Transcript
Constellation Pharmaceuticals Announces First-Quarter 2021 Financial Results and Provides Business Update
Constellation Pharmaceuticals to Host Conference Call to Discuss First Quarter 2021 Results
Constellation Pharmaceuticals, Inc. (CNST) CEO Jigar Raythatha on Q4 2020 Results - Earnings Call Transcript
Constellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2020 Financial Results
Constellation Pharmaceuticals to Participate in the 10th Annual SVB Leerink Global Healthcare Conference
Constellation Pharmaceuticals to Host Conference Call to Discuss Fourth Quarter 2020 Results